ORBIMED ADVISORS LLC (CIK 1055951) reported 98 SEC Form 4 insider transactions across 21 companies over the past 18 months (most recent 2026-08-12). Recent activity: Buy BLSM (1.0M shares), Buy BLSM (1.0M shares), Buy BLSM (625,000 shares), Buy BRVE (9.1M shares), Buy BRVE (1.7M shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-12 | BlossomHill Therapeutics, Inc. (BLSM) | Director | Buy | 1.0M | $0 |
| 2026-08-12 | BlossomHill Therapeutics, Inc. (BLSM) | Director | Buy | 1.0M | $0 |
| 2026-08-12 | BlossomHill Therapeutics, Inc. (BLSM) | Director | Buy | 625,000 | $10.0M |
| 2026-08-11 | Braveheart Bio, Inc. (BRVE) | Director | Buy | 9.1M | $0 |
| 2026-08-11 | Braveheart Bio, Inc. (BRVE) | Director | Buy | 1.7M | $30.0M |
| 2026-08-11 | Braveheart Bio, Inc. (BRVE) | Director | Buy | 273,333 | $4.9M |
| 2026-07-29 | Scribe Therapeutics, Inc. (SCTX) | Director | Buy | 348,825 | $0 |
| 2026-07-29 | Scribe Therapeutics, Inc. (SCTX) | Director | Buy | 1.0M | $15.0M |
| 2026-07-09 | Sionna Therapeutics, Inc. (SION) | Director | Sell | 85,918 | $3.9M |
| 2026-07-02 | Sionna Therapeutics, Inc. (SION) | Director | Sell | 115,844 | $5.3M |
| 2026-06-24 | Enliven Therapeutics, Inc. (ELVN) | 10% Owner | Sell | 787,024 | $35.7M |
| 2026-06-24 | Enliven Therapeutics, Inc. (ELVN) | 10% Owner | Sell | 1,477 | $66,465 |
| 2026-06-24 | Enliven Therapeutics, Inc. (ELVN) | 10% Owner | Sell | 24,846 | $1.1M |
| 2026-06-24 | Enliven Therapeutics, Inc. (ELVN) | 10% Owner | Sell | 46,776 | $2.1M |
| 2026-06-17 | Enliven Therapeutics, Inc. (ELVN) | 10% Owner | Sell | 9,086 | $409,052 |
| 2026-06-17 | Enliven Therapeutics, Inc. (ELVN) | 10% Owner | Sell | 272,322 | $12.3M |
| 2026-06-01 | Q32 Bio Inc. (QTTB) | Director | Buy | 1.2M | $10.0M |
| 2026-06-01 | Q32 Bio Inc. (QTTB) | Director | Buy | 625,000 | $5.0M |
| 2026-05-29 | Sionna Therapeutics, Inc. (SION) | Director | Sell | 101 | $4,493 |
| 2026-05-11 | Sionna Therapeutics, Inc. (SION) | Director | Sell | 48,546 | $2.2M |
| 2026-05-11 | Sionna Therapeutics, Inc. (SION) | Director | Sell | 59,767 | $2.7M |
| 2026-05-11 | Sionna Therapeutics, Inc. (SION) | Director | Sell | 184,639 | $8.5M |
| 2026-04-28 | Traws Pharma, Inc. (TRAW) | 10% Owner | Buy | 597,729 | $998,207 |
| 2026-04-23 | Prelude Therapeutics Inc (PRLD) | Director | Buy | 1.7M | $7.5M |
| 2026-04-23 | Prelude Therapeutics Inc (PRLD) | Director | Buy | 1.1M | $5.0M |
Source: SEC Form 4 filings · as of 2026-08-12